Literature DB >> 22298906

Dysregulation of the microvasculature in nonlesional non-sun-exposed skin of patients with lupus nephritis.

Peter M Izmirly1, Marianna Shvartsbeyn, Shane Meehan, Andrew Franks, Alan Braun, Ellen Ginzler, Sherry X Xu, Herman Yee, Tania L Rivera, Tania Rivera, Charles Esmon, Laura Barisoni, Joan T Merrill, Jill P Buyon, Robert M Clancy.   

Abstract

OBJECTIVE: Membrane endothelial protein C receptor (mEPCR) is highly expressed in peritubular capillaries of kidneys from patients with active and poorly responsive lupus nephritis (LN). We investigated the hypothesis that changes in the microvasculature are widespread with extension to the dermal vasculature.
METHODS: Skin biopsies from uninvolved skin (buttocks) were performed in 27 patients with LN and 5 healthy controls. Sections were stained with specific antibodies reactive with mEPCR, adiponectin, intercellular adhesion molecule-1 (ICAM-1), and CD31; then assessed by enumeration of stained blood vessels (percentage positive blood vessels) blinded to knowledge of clinical information.
RESULTS: There was a significant increase in the prevalence of blood vessels that stained for mEPCR and ICAM-1 in patients compared to controls [94% vs 59% (p = 0.045) and 81% vs 67% (p = 0.037), respectively]. Adiponectin staining and CD31 staining were similar between the groups (45% vs 43% and 98% vs 92%). Dermal staining for mEPCR was greater in patients with proliferative glomerulonephritis than in those with membranous disease (96% vs 60%; p = 0.029). A composite of poor prognostic renal markers and death was significantly associated with greater expression of mEPCR staining.
CONCLUSION: These data are consistent with the notion that in patients with LN, activation of the microvasculature extends beyond the clinically targeted organ. The insidious expression of this widespread vasculopathy may be a contributor to longterm comorbidities.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22298906      PMCID: PMC4054860          DOI: 10.3899/jrheum.110878

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  20 in total

1.  Shedding of endothelial protein C receptor contributes to vasculopathy and renal injury in lupus: in vivo and in vitro evidence.

Authors:  Carlos A Sesin; Xiaoming Yin; Charles T Esmon; Jill P Buyon; Robert M Clancy
Journal:  Kidney Int       Date:  2005-07       Impact factor: 10.612

2.  Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling.

Authors:  Matthias Riewald; Wolfram Ruf
Journal:  J Biol Chem       Date:  2005-03-15       Impact factor: 5.157

3.  Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway.

Authors:  N Ouchi; S Kihara; Y Arita; Y Okamoto; K Maeda; H Kuriyama; K Hotta; M Nishida; M Takahashi; M Muraguchi; Y Ohmoto; T Nakamura; S Yamashita; T Funahashi; Y Matsuzawa
Journal:  Circulation       Date:  2000-09-12       Impact factor: 29.690

4.  Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor.

Authors:  Olga V Volpert; Tetiana Zaichuk; Wei Zhou; Frank Reiher; Thomas A Ferguson; P Michael Stuart; Mohammad Amin; Noel P Bouck
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

5.  Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus.

Authors:  H M Belmont; D Levartovsky; A Goel; A Amin; R Giorno; J Rediske; M L Skovron; S B Abramson
Journal:  Arthritis Rheum       Date:  1997-10

6.  The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex.

Authors:  D J Stearns-Kurosawa; S Kurosawa; J S Mollica; G L Ferrell; C T Esmon
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

7.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

8.  Changes in the distribution pattern of gelatin-binding protein of 28 kDa (adiponectin) in myocardial remodelling after ischaemic injury.

Authors:  Y Ishikawa; Y Akasaka; T Ishii; M Yoda-Murakami; N-H Choi-Miura; M Tomita; K Ito; L Zhang; Y Akishima; M Ishihara; M Muramatsu; M Taniyama
Journal:  Histopathology       Date:  2003-01       Impact factor: 5.087

9.  Thrombomodulin release in baboon sepsis: its dependence on the dose of Escherichia coli and the presence of tumor necrosis factor.

Authors:  H Redl; G Schlag; A Schiesser; J Davies
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

10.  Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited.

Authors:  H M Belmont; J Buyon; R Giorno; S Abramson
Journal:  Arthritis Rheum       Date:  1994-03
View more
  5 in total

1.  A protective Langerhans cell-keratinocyte axis that is dysfunctional in photosensitivity.

Authors:  William D Shipman; Susan Chyou; Anusha Ramanathan; Peter M Izmirly; Sneh Sharma; Tania Pannellini; Dragos C Dasoveanu; Xiaoping Qing; Cynthia M Magro; Richard D Granstein; Michelle A Lowes; Eric G Pamer; Daniel H Kaplan; Jane E Salmon; Babak J Mehrara; James W Young; Robert M Clancy; Carl P Blobel; Theresa T Lu
Journal:  Sci Transl Med       Date:  2018-08-15       Impact factor: 17.956

Review 2.  Diagnostic and prognostic tests in systemic lupus erythematosus.

Authors:  Natalia Vasquez-Canizares; Dawn Wahezi; Chaim Putterman
Journal:  Best Pract Res Clin Rheumatol       Date:  2017-11-06       Impact factor: 4.098

3.  Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis.

Authors:  Evan Der; Saritha Ranabothu; Hemant Suryawanshi; Kemal M Akat; Robert Clancy; Pavel Morozov; Manjunath Kustagi; Mareike Czuppa; Peter Izmirly; H Michael Belmont; Tao Wang; Nicole Jordan; Nicole Bornkamp; Janet Nwaukoni; July Martinez; Beatrice Goilav; Jill P Buyon; Thomas Tuschl; Chaim Putterman
Journal:  JCI Insight       Date:  2017-05-04

Review 4.  Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis.

Authors:  Paul Hoover; Evan Der; Celine C Berthier; Arnon Arazi; James A Lederer; Judith A James; Jill Buyon; Michelle Petri; H Michael Belmont; Peter Izmirly; David Wofsy; Nir Hacohen; Betty Diamond; Chaim Putterman; Anne Davidson
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-01-13       Impact factor: 4.794

Review 5.  Immune Cell-Stromal Circuitry in Lupus Photosensitivity.

Authors:  Ji Hyun Sim; William G Ambler; Isabel F Sollohub; Mir J Howlader; Thomas M Li; Henry J Lee; Theresa T Lu
Journal:  J Immunol       Date:  2021-01-15       Impact factor: 5.422

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.